Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 10, 2013, Pages 4015-4020

  Posch, Christian ^a,b   Moslehi, Homayoun ^a   Feeney, Luzviminda ^a   Green, Gary A ^a   Ebaee, Anoosheh ^a   Feichtenschlager, Valentin ^b   Chong, Kim ^a   Peng, Lily ^a   Dimon, Michelle T ^a   Phillips, Thomas ^a   Daud, Adil I ^c   McCalmont, Timothy H ^d   Leboit, Philip E ^d   Ortiz Urda, Susana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR RECEPTOR; GSK 2126458; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RAPAMYCIN; RAS PROTEIN; TRAMETINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MUTANT; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MEMBRANE PROTEINS; MICE; MICE, NUDE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874613332     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1216013110     Document Type: Article

References (38)

1. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7(4):295-308.
2. Diaz-Flores E, Shannon K (2007) Targeting oncogenic Ras. Genes Dev 21(16):1989-1992.
3. Kratz CP, et al. (2006) Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell Cycle 5(15):1607-1611.
4. Ball NJ et al. (1994) Ras mutations in human melanoma: A marker of malignant progression. J Invest Dermatol 102(3):285-290.
5. Curtin JA, et al. (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135-2147.
6. van't Veer LJ, et al. (1989) N-ras mutations in human cutaneous melanoma from sunexposed body sites. Mol Cell Biol 9(7):3114-3116.
7. van Dijk MCRF, Bernsen MR, Ruiter DJ (2005) Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol 29(9):1145-1151.
8. Eskandarpour M, et al. (2005) Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer 115(1):65-73.
9. Jaiswal BS, et al. (2009) Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS ONE 4(5):e5717.
10. Kelleher FC, McArthur GA (2012) Targeting NRAS in melanoma. Cancer J 18(2): 132-136.
11. Chapman PB, et al. (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9): 2745-2751.
12. Ascierto P, et al. (2012) Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAF V600 or NRAS mutations. J Clin Oncol 30(Suppl):8511.
13. Wan PTC, et al.; Cancer Genome Project (2004) Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855-867.
14. Heerding DA, et al. (2008) Identification of 4-(2-(4-amino-1, 2, 5-oxadiazol-3-yl)-1- ethyl-7-[(3S)-3-piperidinylmethyl]oxy-1H-imidazo[4, 5-c]pyridin-4-yl)-2-methyl-3-butyn- 2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem 51(18):5663-5679.
15. Han EK-H, et al. (2007) Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 26(38):5655-5661.
16. Khalili JS, et al. (2012) Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 18(16):4345-4355.
17. Chou T-C (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621-681.
18. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9(17):6483-6488.
19. Devitt B, et al. (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24(4):666-672.
20. Mishra PJ, et al. (2010) Dissection of RAS downstream pathways in melanomagenesis: A role for Ral in transformation. Oncogene 29(16):2449-2456.
21. Giehl K (2005) Oncogenic Ras in tumour progression and metastasis. Biol Chem 386(3): 193-205.
22. Roberts PJ, et al. (2012) Combined PI3K/mTOR and MEK inhibition provides broad anti-tumor activity in faithful murine cancer models. Clin Cancer Res 18(19):5290-5303.
23. Simmons BH, et al. (2012) Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice. Cancer Chemother Pharmacol 70(2):213-220.
24. Kinross KM, et al. (2011) In vivo activity of combined PI3K/mTOR andMEK inhibition in a Kras (G12D);Pten deletion mouse model of ovarian cancer. Mol Cancer Ther 10(8):1440-1449.
25. Collisson EA, et al. (2012) A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2(8):685-693.
26. Atefi M, et al. (2011) Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS ONE 6(12):e28973.
27. Greger JG, et al. (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11(4):909-920.
28. Kwong LN, et al. (2012) Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18(10):1503-1510.
29. She Q-B, et al. (2010) 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18(1):39-51.
30. Solit DB, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439(7074):358-362.
31. Kiessling MK, et al. (2011) High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood 117(8):2433-2440.
32. Gupta S, et al. (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129(5):957-968.
33. von Euw E, et al. (2012) Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer 11:22.
34. Espona-Fiedler M, et al. (2012) Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: Prodigiosin vs. obatoclax. Biochem Pharmacol 83(4):489-496.
35. Sos ML, et al. (2009) Identifying genotype-dependent efficacy of single and combined PI3Kand MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 106(43):18351-18356.
36. Aksamitiene E, Kiyatkin A, Kholodenko BN (2012) Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: A fine balance. Biochem Soc Trans 40(1):139-146.
37. Carracedo A, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118(9): 3065-3074.
38. Galoian K, Temple HT, Galoyan A (2012) mTORC1 inhibition and ECM-cell adhesionindependent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops. Tumour Biol 33(3):885-890.